01:33 PM EDT, 03/20/2026 (MT Newswires) -- ImmunityBio ( IBRX ) said Friday that the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China, approved Anktiva, or nogapendekin alfa inbakicept-pmln, marking the drug's first authorization in Asia.

The drug is approved for use in combination with Bacillus Calmette-Guerin to treat adults with BCG-unresponsive non-muscle invasive bladder cancer, including carcinoma in situ with or without papillary tumors, consistent with its approved use in the US.

The authorization follows prior reviews by the US Food and Drug Administration and the European Medicines Agency, in line with local regulatory requirements. ImmunityBio ( IBRX ) added that it continues discussions with other regulators in Asia as part of its international regulatory strategy.

Price: 8.88, Change: +0.06, Percent Change: +0.68